Antineoplaston induces G1 arrest by PKCα and MAPK pathway in SKBR-3 breast cancer cells

Oncology Reports

Volumn 14, Issue 2, 2005, Pages 489-494

  Fujii, Teruhiko ^a   Nakamura, Anna M ^a   Yokoyama, Goro ^a   Yamaguchi, Miki ^a   Tayama, Kosuke ^a   Miwa, Keisuke ^a   Toh, Uhi ^a   Kawamura, Daisuke ^a   Shirouzu, Kazuo ^a   Yamana, Hideaki ^a   Kuwano, Michihiko ^a   Tsuda, Hideaki ^b  

^a KURUME UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b Social Insurance Kurume Daiichi Hospital   (Japan)

Author keywords

Antineoplaston; ERK MAPK; PKC; SKBR 3 breast cancer cells

Indexed keywords

12 (2 CYANOETHYL) 6,7,12,13 TETRAHYDRO 13 METHYL 5 OXOINDOLO[2,3 A]PYRROLO[3,4 C]CARBAZOLE; 3 PHENYLACETAMIDO 2,6 PIPERIDINEDIONE; BENZENEACETAMIDE DERIVATIVE; CARBAZOLE DERIVATIVE; CDKN1A PROTEIN, HUMAN; CELL CYCLE PROTEIN; CYCLIN DEPENDENT KINASE INHIBITOR 1A; CYCLIN DEPENDENT KINASE INHIBITOR 1B; CYCLINE; ENZYME INHIBITOR; INDOLE DERIVATIVE; ISOENZYME; MITOGEN ACTIVATED PROTEIN KINASE; PIPERIDONE DERIVATIVE; PRKCA PROTEIN, HUMAN; PROTEIN KINASE C; PROTEIN KINASE C ALPHA; PROTEIN P16INK4A; RETINOBLASTOMA PROTEIN; TUMOR SUPPRESSOR PROTEIN;

ARTICLE; BREAST TUMOR; CELL CYCLE G1 PHASE; CELL PROLIFERATION; COMPARATIVE STUDY; DOSE RESPONSE; DRUG ANTAGONISM; DRUG EFFECT; FLOW CYTOMETRY; HUMAN; METABOLISM; PATHOLOGY; PHOSPHORYLATION; SIGNAL TRANSDUCTION; TIME; TUMOR CELL LINE; WESTERN BLOTTING;

BENZENEACETAMIDES; BLOTTING, WESTERN; BREAST NEOPLASMS; CARBAZOLES; CELL CYCLE PROTEINS; CELL LINE, TUMOR; CELL PROLIFERATION; CYCLIN-DEPENDENT KINASE INHIBITOR P16; CYCLIN-DEPENDENT KINASE INHIBITOR P21; CYCLIN-DEPENDENT KINASE INHIBITOR P27; CYCLINS; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME INHIBITORS; FLOW CYTOMETRY; G1 PHASE; HUMANS; INDOLES; ISOENZYMES; MAP KINASE SIGNALING SYSTEM; MITOGEN-ACTIVATED PROTEIN KINASES; PHOSPHORYLATION; PIPERIDONES; PROTEIN KINASE C; PROTEIN KINASE C-ALPHA; RETINOBLASTOMA PROTEIN; TIME FACTORS; TUMOR SUPPRESSOR PROTEINS;

EID: 24744456599     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.14.2.489     Document Type: Article

References (29)

1. Burzynski SR: Antineoplastons: biochemical defence against cancer. Physiol Chem Phys 8: 275-279, 1976.
2. Burzynski SR: The present state of antineoplaston research (1). Integr Cancer Ther 3: 47-58, 2004.
3. Tsuda H, Sata M, Kumabe T, Uchida M and Hara H: The preventive effect of antineoplaston AS2-1 on HCC recurrence. Oncol Rep 10: 391-397, 2003.
4. Tsuda H, Sata M, Ijuuin H, Kumabe T, Uchida M, Ogou Y, Akagi Y, Shirouzu K, Hara H and Nakashima Y: A novel strategy for remission induction and maintenance in cancer therapy. Oncol Rep 9: 65-68, 2002.
5. Tsuda H, Sata M, Kumabe T, Hara H, Eriguchi N, Sugita Y and Nagamatsu H: Quick response of advanced cancer to chemoradiation therapy with antineoplastons. Oncol Rep 5: 597-600, 1998. (Pubitemid 28189310)
6. Kumabe T, Tsuda H, Uchida M, Ogoh Y, Hayabuchi N, Sata M, Nakashima O and Hara H: Antineoplaston treatment for advanced hepatocellular carcinoma. Oncol Rep 5: 1363-1367, 1998. (Pubitemid 28474075)
7. Badria F, Mabed M, El-Awadi M, Abou-Zeid L, Al-Nashar E and Hawas S: Immune modulatory potentials of antineoplaston A-10 in breast cancer patients. Cancer Lett 157: 57-63, 2000. (Pubitemid 30421232)
8. Takai Y, Kishimoto A, Inoue M and Nishizuka Y: Studies on acyclic nucleotide-independent protein kinase and its proenzyme in mammalian tissues. I. Purification and characterization of an active enzyme from bovine cerebellum. J Biol Chem 252: 7603-7609, 1977. (Pubitemid 8227336)
9. Nishizuka Y: The molecular heterogeneity of protein kinase C and its implications for cellular regulation. Nature 334: 661-665, 1984.
10. Nishizuka Y: Intracellular signaling hydrolysis of phospholipids and activation of protein kinase C. Science 258: 607-614, 1992.
11. Nishizuka Y: Protein kinase C and lipid signaling for sustained cellular responses. FASEB J 9: 484-496, 1995.
12. Musashi M: The roll of protein kinase C isoform in cell proliferation and apoptosis. Int J Hematol 72: 12-19, 2000.
13. Akkaraju GR and Basu A: Overexpression of protein kinase C-λ attenuates caspase activation and tumor necrosis factor-α-induced cell death. Biochem Biophys Res Commun 279: 103-107, 2000.
14. Basu A: Differential sensitivity of breast cancer cells to tumor necrosis factor-α: involvement of protein kinase C. Biochem Biophys Res Commun 280: 883-891, 2001.
15. Gauthier ML, Torretto C, Ly J, Francescutti V and O'Day DH: Protein kinase Cα negatively regulates cell spreading and motility in MDA-MB-231 human breast cancer cells downstream of epidermal growth factor receptor. Biochem Biophys Res Commun 307: 839-846, 2003. (Pubitemid 36871649)
16. Soh JW, Lee YS and Weinstein IB: Effects of regulatory domains of specific isoforms of protein kinase C on growth control and apoptosis in MCF-7 breast cancer cells. J Exp Ther Oncol 3: 115-126, 2003.
17. Shtutman M, Hershko T, Maissel A, Fima E and Livneh E: PKCλ associates with cyclin E/Cdk2 complex in serum-starved MCF-7 and NIH-3T3 cells. Exp Cell Res 286: 22-29, 2003. (Pubitemid 36506855)
18. Mao M, Fang X, Lu Y, Lapushin R, Bast RC Jr and Mills GB: Inhibition of growth-factor-induced phosphorylation and activation of protein kinase B/Akt by atypical protein kinase C in breast cancer cells. Biochem J 2: 475-482, 2000. (Pubitemid 32011441)
19. Cowley S, Paterson H, Kemp P and Marshall CJ: Activation of MAP kinase kinase is necessary and sufficient for PC12 differentiation and for transformation of NIH 3T3 cells. Cell 77: 841-852, 1994. (Pubitemid 24187682)
20. Mansour SJ, Matten WT, Hermann AS, Candia JM, Rong S, Fukasawa K, Vande Woude GF and Ahn NG: Transformation of mammalian cells by constitutively active MAP kinase kinase. Science 265: 966-970, 1994. (Pubitemid 24281496)
21. Keshamouni VG, Mattingly RR and Reddy KB: Mechanism of 17-β-estradiol-induced Erk1/2 activation in breast cancer cells. A role for HER2 AND PKC-δ. J Biol Chem 277: 22558-22565, 2002. (Pubitemid 34967232)
22. Greco S, Muscella A, Elia MG, Salvatore P, Storelli C, Mazzotta A, Manca C and Marsigliante S: Angiotensin II activates extracellular signal regulated kinases via protein kinase C and epidermal growth factor receptor in breast cancer cells. J Cell Physiol 196: 370-377, 2003. (Pubitemid 36775885)
23. Le XF, Marcelli M, McWatters A, Nan B, Mills GB, O'Brian CA and Bast RC Jr: Heregulin-induced apoptosis is mediated by down-regulation of Bcl-2 and activation of caspase-7 and is potentiated by impairment of protein kinase C α activity. Oncogene 20: 8258-8269, 2001. (Pubitemid 34038213)
24. Tsuda H, Iemura A, Sata M, Uchida M, Yamana K and Hara H: Inhibitory effect of antineoplaston A10 and AS2-1 on human hepatocellular carcinoma. Kurume Med J 43: 137-147, 1996.
25. Schonwasser DC, Marais RM, Marshall CJ and Parker PJ: Activation of the mitogen-activated protein kinase/extracellular signal-regulated kinase pathway by conventional, novel and atypical protein kinase C isotypes. Mol Cell Biol 18: 790-798, 1998. (Pubitemid 28063412)
26. Yoon YM, Oh CD, Kim DY, Lee YS, Park JW, Huh TL, Kang SS and Chun JS: Epidermal growth factor negatively regulates chondrogenesis of mesenchymal cells by modulating the protein kinase C-α, Erk-1 and p38 MAPK signaling pathways. J Biol Chem 275: 12353-12359, 2000.
27. Lo LW, Cheng JJ, Chiu JJ, Wung BS, Liu YC and Wang DL: Endothelial exposure to hypoxia induces Egr-1 expression involving PKC α-mediated Ras/Raf-1/ERK1/2 pathway. J Cell Physiol 188: 304-312, 2001.
28. Meyerson M and Harlow E: Identification of G1 kinase activity for cdk6, a novel cyclin D partner. Mol Cell Biol 14: 2077-2086, 1994.
29. Draetta G: Cell cycle control in eukaryotes: molecular mechanisms of cdc2 activation. Trends Biochem Sci 15: 378-383, 1990.